% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Bertho:358325,
author = {Bertho, Annaïg and Graeff, Christian and Ortiz, Ramon and
Giorgi, Maria and Schuy, Christoph and Juchaux, Marjorie and
Gilbert, Cristèle and Espenon, Julie and Oppermann, Julius
and Sokol, Olga and Tinganelli, Walter and Prezado, Yolanda},
title = {{C}arbon minibeam radiation therapy results in tumor growth
delay in an osteosarcoma murine model},
journal = {Scientific reports},
volume = {15},
number = {1},
issn = {2045-2322},
address = {[London]},
publisher = {Springer Nature},
reportid = {GSI-2025-00509},
pages = {7305},
year = {2025},
note = {This article is licensed under a Creative Commons
Attribution-NonCommercial-NoDerivatives 4.0 International
License},
abstract = {Despite remarkable advances, radiation therapy (RT) remains
inefficient for some bulky tumors, radioresistant tumors,
and certain pediatric tumors. Minibeam radiation therapy
(MBRT) has emerged as a promising approach, reducing normal
tissue toxicity while enhancing immune responses.
Preclinical studies using X-rays and proton MBRT have
demonstrated enhanced therapeutic index for aggressive tumor
models. Combining MBRT's advantages of spatial dose
fractionation with the physical and biological benefits of
carbon ions could be a step further toward unleashing the
full potential of MBRT. This study aims to perform the first
in vivo study of local and systemic responses of a
subcutaneous mouse osteosarcoma (metastatic) model to carbon
MBRT (C-MBRT) versus conventional carbon ion therapy (CT).
Irradiations were conducted at the GSI Helmholtz Centre in
Germany using 180 MeV/u 12C ions beam. All irradiated
animals received an average dose (20 Gy) and displayed a
significant and similar tumor growth delay in addition to a
decreased metastasis score compared to the non-irradiated
group. In the C-MBRT group, $70\%$ of the tumor volume
received the valley dose, which is a very low dose of 1.5
Gy. The remaining $30\%$ of the tumor received the peak dose
of 105 Gy, resulting in an average dose of 20 Gy. These
results suggest that C-MBRT triggered distinct mechanisms
from CT and encourage further investigations to confirm the
potential of C-MBRT for efficient treatment of
radioresistant tumors.},
keywords = {Animals / Osteosarcoma: radiotherapy / Osteosarcoma:
pathology / Mice / Heavy Ion Radiotherapy: methods / Disease
Models, Animal / Cell Line, Tumor / Bone Neoplasms:
radiotherapy / Bone Neoplasms: pathology / Carbon / Tumor
Burden: radiation effects / Carbon ions (Other) / Carbon
minibeam radiation therapy (C-MBRT) (Other) / Carbon therapy
(Other) / Minibeam radiation therapy (Other) / Osteosarcoma
(Other) / Radioresistant tumor (Other) / Carbon (NLM
Chemicals)},
cin = {BIO},
ddc = {600},
cid = {I:(DE-Ds200)BIO-20160831OR354},
pnm = {633 - Life Sciences – Building Blocks of Life: Structure
and Function (POF4-633) / FAIR Phase-0 - FAIR Phase-0
Research Program (GSI-FAIR-Phase-0) / HITRIplus - Heavy Ion
Therapy Research Integration plus (101008548) / PROTONMBRT -
Spatial fractionation of the dose in proton therapy: a novel
therapeutic approach (817908)},
pid = {G:(DE-HGF)POF4-633 / G:(Ds200)GSI-FAIR-Phase-0 /
G:(EU-Grant)101008548 / G:(EU-Grant)817908},
experiment = {$EXP:(DE-Ds200)SBio08_Prezado-20200803$},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:40025099},
UT = {WOS:001435489800024},
doi = {10.1038/s41598-025-91872-6},
url = {https://repository.gsi.de/record/358325},
}